Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Heterogeneity of poststroke cognitive disorders: Diagnostic and therapeutic aspects

Full Text:


The paper considers the clinical features and mechanisms of recovery of motor and cognitive functions after prior stroke. To treat stroke as soon as possible is emphasized to determine to a large extent the success of further rehabilitation measures. The most significant recovery is observed in the first 3 months after stroke; there may be generally only a slight worsening following 6 months. However, the recovery process may last longer in a number of patients. There are data on the use of nicergoline (Sermion®) in this category of patients.

About the Author

Igor Vladimirovich Damulin

Department of Nervous System Diseases


1. <div><p>Дамулин И.В. Постинсультные двигательные нарушения. Cons med 2002;5(2):64—70.</p><p>Кадыков А.С., Шахпаронова Н.В. Реабилитация после инсульта. РМЖ 2003;11(25):1390—4.</p><p>Парфенов В.А. Постинсультная спастичность и ее лечение. РМЖ 2006;14(9):689—93.</p><p>Koek H.L., Bots M.L., Grobbee D.E. Are Russians different than other Europeans in their relation of risk factors to cardiovascular disease risk. Eur J Epidemiol 2003;18:843-4.</p><p>Patel M.D., Coshall C., Rudd A.G. et al. Cognitive impairment after stroke: clinical determinants and its association with long-term stroke outcomes. J Am Geriatr Soc 2002;50:700-6.</p><p>Tang W.K., Chan S.S, Chiu H.F. et al. Frequency and clinical determinants of poststroke cognitive impairment in nondemented stroke patients. J Geriatr Psychiatr Neurol 2006;19:65—71.</p><p>Pasquier F., Leys D. Why are stroke patients prone to develop dementia? J Neurol 1997;244:135—42.</p><p>Gorelick P.B. Status of risk factors for dementia associated with stroke. Stroke 1997;28:459—63.</p><p>Leys D., Henon H., Pasquier F. The role of cerebral infarcts in vascular dementia. In: Research and Practice in Alzheimer’s Disease. V. 5. B.Vellas et al. (eds). Paris: Serdi Publisher, 2001;123—8.</p><p>Binder J., Marshall R., Lazar R. et al. Distinct syndromes of hemineglect. Arch Neurol 1994;49:1187—94.</p><p>Maeshima S., Truman G., Smith D.S. et al. Is unilateral spatial neglect a single phenomenon? J Neurol 1997;244:412-7.</p><p>Rode G., Revol P., Rossetti Y. et al. Looking while imagining. The influence of visual input on representational neglect. J Neurol 2007;68:432—7.</p><p>Smania N., Martini M.C., Gambina G. et al. The spatial distribution of visual attention in hemineglect and extinction patients. Brain 1998;121:1759—70.</p><p>Classen J., Schnitzler A., Binkofski F. et al. The motor syndrome associated with exaggerated inhibition within the primary motor cortex of patients with hemiparetic stroke. Brain 1997;120:605—19.</p><p>Kollen B., Van de Port I., Lindeman E. et al. Preicting improvement in gait after stroke. Stroke 2005;36:2676-80.</p><p>Haggard P., Cockburn J., Cock J. et al. Interference between gait and cognitive tasks in a rehabilitating neurological population. J Neurol Neurosurg Psychiatry 2000;69:479-86.</p><p>Carmichael S.T. Plasticity of cortical projections after stroke. Neuroscientist 2003;9:64—75.</p><p>Stroemer R.P., Kent T.A., Hulsebosch C.E. Neocortical neural sprouting, synaptogenesis, and behavioral recovery after neocortical infarction in rats. Stroke 1995;26:2135-44.</p><p>Виндиш М. Лекарства, усиливающие когнитивные функции (ноотропы). М.: ЭБЕВЕ, 2001;23 с.</p><p>Одинак М.М., Емелин А.Ю., Лобзин В.Ю. Нарушения когнитивных функций при цереброваскулярной патологии. СПб.: ВМедА, 2006;158 с.</p><p>Руденко Г.М., Музыченко А.П. Результаты клинического изучения препарата сермион (анализ данных Фармакологического комитета). М., 1987;31 с.</p><p>Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции. Руководство для врачей. 2-е изд. М.: МЕДпресс-информ, 2010; 272 с.</p><p>Crook T.H. Nicergoline: Parallel evolution of clinical trial methodology and drug development in dementia. Dement Geriatr Cogn Disord 1997;8(Suppl 1):22—6.</p><p>Winblad B., Carfagna N., Bonura L. et al. Nicergoline in dementia. A review of its pharmacological properties and therapeutic potential. С^ Drugs 2000;14;267—87.</p><p>Winblad B., Fioravanti M., Dolezal T. et al. Therapeutic use of nicergoline. Clin Drug Invest 2008;28:533—52.</p><p>Nappi G., Bono G., Merlo G. et al. Longterm nicergoline treatment of mild to moderate senile dementia. Results of a multicentre, double-blind, placebo-controlled study. Clin Drug Invest 1997;13:308-16.</p><p>Bes A., Orgogozo J.-M., Poncet M. et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999;6:313—22.</p></div><br />


For citations:

Damulin I.V. Heterogeneity of poststroke cognitive disorders: Diagnostic and therapeutic aspects. Neurology, Neuropsychiatry, Psychosomatics. 2013;5(1):27-33. (In Russ.)

Views: 664

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)